Krystal Biotech (KRYS) Non-Current Assets (2016 - 2026)

Krystal Biotech has disclosed Non-Current Assets across 11 years of filings, most recently posting $377.2 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $377.2 million, up 22.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 15.32% YoY), and the FY2025 annual result was $309.2 million, down 1.47% from the prior year.
• Non-Current Assets came in at $377.2 million for Q1 2026 at Krystal Biotech, up from $309.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $377.2 million in Q1 2026 to a low of $172.6 million in Q2 2022.
• The 5-year median for Non-Current Assets is $234.9 million (2024), against an average of $246.7 million.
• Peak annual rise in Non-Current Assets reached 380.95% in 2022, while the deepest fall reached 5.08% in 2022.
• Krystal Biotech's Non-Current Assets stood at $174.7 million in 2022, then surged by 31.93% to $230.4 million in 2023, then surged by 36.17% to $313.8 million in 2024, then retreated by 1.47% to $309.2 million in 2025, then gained by 22.0% to $377.2 million in 2026.
• The last three Non-Current Assets figures came in at $377.2 million (Q1 2026), $309.2 million (Q4 2025), and $314.4 million (Q3 2025), per Business Quant data.